COMMUNIQUÉS West-GlobeNewswire

Assure Holdings Closes $3 Million Loan Facility
14/02/2019
New Agreement Features $2 Million Term Loan and $1 Million Line of Credit to Help Fund Expansion DENVER, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “ Company ” or “ Assure ”) (TSXV: IOM; OTCPK: ARHH), [...]
American Cannabis Company, Inc. Announces Hemp Business Development & Appointment of Chief Operations Officer
14/02/2019
DENVER, CO, Feb. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American Cannabis Company, Inc. (OTCQB: AMMJ) (“ACC”), a full-service business-to-business consulting solutions provider, and seller of ancillary [...]
Achaogen Submits Response to ASPR/BARDA Request for Information (RFI) for Antimicrobial Resistance Project BioShield
14/02/2019
-- Plazomicin may be well-suited to play a critical role in biodefense preparedness -- SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company [...]
Achaogen Provides Update on Corporate Progress and Key Preliminary Fourth Quarter 2018 Results
14/02/2019
-- Company provides update on ZEMDRI ® commercialization and launch -- -- Data from both the EPIC and CARE Phase 3 clinical studies of plazomicin are expected in peer-reviewed publication -- SOUTH SAN FRANCISCO, Calif [...]
Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita® (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)
14/02/2019
Results Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy NOVATO, Calif., TOKYO and LONDON, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: [...]
Precipio 2018 Revenues Increase 66% over 2017; Company Takes Substantial Cost-Cutting Measures Towards Profitability
14/02/2019
Shareholder call scheduled for February 21st at 4:30PM EST NEW HAVEN, Conn., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced today its preliminary unaudited [...]
Fortune Magazine names Stryker one of the 100 Best Companies to Work For in 9th consecutive year
14/02/2019
Kalamazoo, Michigan, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Kalamazoo, Michigan – February 14, 2019 – Stryker (NYSE:SYK) announced today it has been named one of Fortune’s 2019 100 Best Companies to Work For in its annual [...]
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
14/02/2019
Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites 24% of randomized patients have already completed the studies On track to report topline [...]
Medtronic and Medical University of South Carolina Partner to Improve Patient Outcomes
14/02/2019
Value-Based Health Care Partnership Will Target Acute Conditions and Chronic Diseases in South Carolina DUBLIN and CHARLESTON, S.C. - February 14, 2019 - Medtronic plc (NYSE:MDT) and the Medical University of South [...]
Milestone Scientific Announces Private Placement by Entity Affiliated with Board Member & CEO of the Company’s Wand Dental Subsidiary
14/02/2019
LIVINGSTON, N.J., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS) today announced that BP4 S.p.A. (“BP4”), a principal stockholder of Milestone Scientific, exercised its right to participate on [...]
Foamix Pharmaceuticals Fourth Quarter Financial Results Conference Call & Webcast Scheduled for March 1
14/02/2019
REHOVOT, Israel, and BRIDGEWATER, N.J., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and [...]
Annual General Meeting in ALK-Abelló A/S on 13 March 2019
14/02/2019
ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ): The annual general meeting of ALK-Abelló A/S will take place on Wednesday 13 March 2019 at 16:00 (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark. The agenda of [...]
Athersys to Host Year-End 2018 Financial Results Call
14/02/2019
CLEVELAND, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) will release its year-end 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, March 14, 2019, and will host a conference [...]
Passage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases
14/02/2019
Industry veterans Stephen Squinto, Ph.D. and Tachi Yamada, M.D. team up with gene therapy pioneer James Wilson, M.D., Ph.D. to launch new world-class CNS-focused gene therapy company PHILADELPHIA, Feb. 14, 2019 (GLOBE [...]
Inspire Medical Systems, Inc. to Present at the 8th Annual SVB Leerink Global Healthcare Conference
14/02/2019
MINNEAPOLIS, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative and minimally invasive [...]
HealthEC Announces Hiring of Robert Osburn as Chief Operating Officer
14/02/2019
Longtime healthcare management executive to oversee operations and grow portfolio of clients using the firm’s population health management platform for value-based contracting EDISON, N.J., Feb. 14, 2019 (GLOBE NEWSWIRE [...]
DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
14/02/2019
MINNEAPOLIS, Feb. 14, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that it has initiated dosing patients with chronic kidney disease (“CKD [...]
IntelGenx Announces Montreal’s Douglas Mental Health University Institute as Ninth Montelukast VersaFilm™ Phase 2a Clinical Trial Site
14/02/2019
Renowned Neurologist Dr. Serge Gauthier to Serve as Site’s Lead Investigator SAINT LAURENT, Quebec, Feb. 14, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery [...]
Replimune Reports Financial Results for the Third Fiscal Quarter, Ended December 31, and Provides Development and Corporate Update
14/02/2019
RP1: Completed Single Agent Enrollment in Part 1 Portion of Phase 1/2 Clinical Trial in the UK; Part 1 Enrollment Opened for Combination with Nivolumab in Patients with Solid Tumors in the US RP1: Opening of Part 2 in [...]

Pages